A Phase I, Open-Label Drug-Drug Interaction Trial to Investigate the Effect of TMC278 25 mg q.d. on the Steady State Pharmacokinetics of Ethinylestradiol and Norethindrone, in Healthy Women.

Trial Profile

A Phase I, Open-Label Drug-Drug Interaction Trial to Investigate the Effect of TMC278 25 mg q.d. on the Steady State Pharmacokinetics of Ethinylestradiol and Norethindrone, in Healthy Women.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2013

At a glance

  • Drugs Rilpivirine (Primary) ; Ethinylestradiol/norethisterone
  • Indications HIV-1 infections; Pregnancy
  • Focus Pharmacokinetics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top